Moderna Inc.
Moderna Reports 2025 Performance and Outlines 2026 Outlook
Summary
Moderna, Inc. reported a productive year in 2025 despite challenging conditions, with significant operational achievements including multiple regulatory approvals, commercial execution, and financial discipline. The company achieved a nearly $1 billion reduction in financial cash costs, expanded its pipeline across seasonal vaccines, oncology, and rare diseases, and secured a $1.5 billion term loan facility. Moderna anticipates continued financial discipline and investment in its pipeline to drive future sales growth, with a focus on launching new infectious disease products and geographic expansion. The company also highlighted advancements in technology and AI to enhance operational efficiency and accelerate decision-making.
Get alerts for MRNA
Be first to know when Moderna Inc. files with the SEC.
Filing Categories
About Moderna Inc.
Moderna Inc. is a biotechnology company focused on developing transformative medicines based on messenger RNA (mRNA) technology. Its primary function is to research and produce a broad spectrum of vaccines and therapeutics by leveraging its proprietary mRNA technology platform. Moderna is notably recognized for its pivotal role in the healthcare and pharmaceutical sector, particularly due to its development of one of the first COVID-19 vaccines to receive emergency use authorization. The company’s pipeline extends beyond infectious diseases, targeting therapeutic areas such as oncology, cardiovascular diseases, and rare genetic disorders. Headquartered in Cambridge, Massachusetts, Moderna takes a leading position in the biotechnology industry through its innovative approach to drug development, emphasizing rapid advancement from concept to clinical application. The company plays a crucial role in addressing global health challenges through its cutting-edge mRNA-based solutions.
Official SEC Documents